Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease

LaTonya J. Hickson(Jacksonville College), James L. Kirkland(Cedars-Sinai Medical Center), Daniel M. Koerber(Mayo Clinic in Florida), Nino Giorgadze(Mayo Clinic in Florida), Mark Wentworth(Mayo Clinic in Florida), Nathan K. LeBrasseur(WinnMed), Ailing Xue(Mayo Clinic in Florida), Robert J. Pignolo(Mayo Clinic in Arizona), Kyra L. Jordan(WinnMed), Sundeep Khosla(WinnMed), Lilach O. Lerman(Mayo Clinic), Tamar Tchkonia(Cedars-Sinai Medical Center), Qingyi Jia(WinnMed), Ishran M. Saadiq(WinnMed), Tammie L. Volkman(WinnMed), Travis J. McKenzie(Mayo Clinic), Tamara K. Evans(WinnMed), Stella Victorelli(Mayo Clinic in Florida), Kalli K. Schaefer(Mayo Clinic in Florida), Tamar Pirtskhalava(Mayo Clinic in Florida), Shane A. Bobart(WinnMed), Erin O. Wissler Gerdes(University of Iowa), Anthony B. Lagnado(Mayo Clinic), Donna K. Lawson(Mayo Clinic Hospital), Larissa Prata(Cedars-Sinai Medical Center), Sandra M. Herrmann(Mayo Clinic), Shahrukh Hashmi(Abu Dhabi Health Services), Yi Zhu(University of Macau), Todd A. Kellogg(WinnMed), Kathleen M. McDonald(Mayo Clinic in Florida), Michael D. Jensen(Mayo Clinic), Stephen C. Textor(Textron Systems (United Kingdom)), João F. Passos(Newcastle University)
EBioMedicine
September 1, 2019
Cited by 1,317


Related Papers